# Agenda

## Wednesday September 7, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00pm</td>
<td>Registration – Honoré Ballroom</td>
</tr>
<tr>
<td>7:00pm</td>
<td>Welcome Reception (Cocktails &amp; Dinner) - Crystal Room- (3rd Floor)</td>
</tr>
<tr>
<td>8:00pm</td>
<td>Opening Remarks</td>
</tr>
</tbody>
</table>

## Thursday September 8, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am</td>
<td>Breakfast – Potter’s</td>
</tr>
</tbody>
</table>

### Session #1

Honoré Ballroom (Lobby Level) 8:00 am – 12:15pm
Chemotherapy Induced Peripheral Neuropathy (CIPN) Preclinical Studies & Outcome Measures

Moderators – Ahmet Höke MD, PhD – Professor of Neurology & Neuroscience, Director, DB Drachman Division of Neuromuscular Disorders - Johns Hopkins University School of Medicine & A. Gordon Smith, MD – Professor of Neurology, Chief, Division of Neuromuscular Medicine, University of Utah

### TOPIC #1 – MECHANISMS OF AXONAL DEGENERATION AND PRECLINICAL ANIMAL MODES IN CIPN

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am</td>
<td>Mechanisms of Axon Degeneration in CIPN</td>
</tr>
<tr>
<td></td>
<td>Aaron DiAntonio, MD, PhD, Professor of Developmental Biology</td>
</tr>
<tr>
<td></td>
<td>Washington University School of Medicine</td>
</tr>
<tr>
<td>8:30am</td>
<td>Mechanisms and Genetics of CIPN</td>
</tr>
<tr>
<td></td>
<td>Nathan P. Staff, MD, PhD, Assistant Professor of Neurology - Mayo Clinic</td>
</tr>
<tr>
<td>9:00am</td>
<td>Mitotoxicity as the cause of CIPN</td>
</tr>
<tr>
<td></td>
<td>Garry Bennett, PhD, Professor Anesthesiology - University of California, San Diego</td>
</tr>
<tr>
<td>9:30am</td>
<td>Panel Discussion &amp; Audience Participation</td>
</tr>
<tr>
<td>9:55am</td>
<td>Break</td>
</tr>
</tbody>
</table>

### TOPIC #2 –CLINICAL AND PRECLINICAL OUTCOME MEASURES SPECIFIC TO CIPN

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:20am</td>
<td>Comparison of Outcome Measures in Animal Models &amp; Human Trials</td>
</tr>
<tr>
<td></td>
<td>Guido Cavaletti, MD, PhD, Professor School of Medicine and Surgery - University of Milano-Bicocca</td>
</tr>
<tr>
<td>10:50am</td>
<td>CI-PeriNomS: Clinical and Electrophysiological Outcome Measures in CIPN</td>
</tr>
<tr>
<td></td>
<td>Kathleen Griffith, PhD, MPH, CRNP, Assistant Professor - University of Maryland, School of Nursing</td>
</tr>
<tr>
<td>11:20am</td>
<td>CIPN Trials: Oncologist's Perspective</td>
</tr>
<tr>
<td></td>
<td>Joanna Brell, MD, Associate Director, Cancer Center for Clinical Research - Metro Health Medical Center</td>
</tr>
<tr>
<td>11:50pm</td>
<td>Panel Discussion &amp; Audience Participation</td>
</tr>
<tr>
<td>12:15pm</td>
<td>Lunch – Potter’s</td>
</tr>
</tbody>
</table>
Thursday September 8, 2016 (cont.)

Session #2
Honoré Ballroom - 1:00pm – 6:00pm
New & Developing Drugs: What's in the Pipeline
Moderator – Roy Freeman, MD - Professor of Neurology, Director, Center for Autonomic and Peripheral Nerve Disorders
Beth Israel Deaconess Medical Center, Harvard Medical School

TOPIC #1 – WHAT’S IN THE PIPELINE – PART 1

1:05pm – 1:30pm  Selective Sodium Channel Blockers
Simon Tate, PhD, Vice President and Head of Pain - Convergence A Biogen Company

1:35pm – 2:00pm  Muscarinic Receptor Antagonism to Treat Peripheral Neuropathy
Paul Fernyhough, PhD, BSc, Professor Pharmacology & Therapeutics - University of Manitoba

2:05pm – 2:30pm  NEO6860, a Novel TRPV1 Modality Selective Antagonist: Key in Vitro Data and Result from a Phase I Study
Dan Chiche, MD.  Vice President Clinical Development & Medical Affairs - NÉOMED Institute

2:35pm – 3:00pm  TRPA1 Antagonists for the Treatment of Painful Peripheral Neuropathies
Magdalene Moran, PhD, Senior Vice President, Biology - Hydra Biosciences, Inc.

3:05pm – 3:30pm  Panel Discussion & Audience Participation

3:35pm – 4:00pm  Break

TOPIC #2 – WHAT’S IN THE PIPELINE – PART 2

4:05pm – 4:30pm  Gene Transfer of NT3 to Prevent CIPN
David Fink, MD, Robert Brear Professor and Chair, Department of Neurology - University of Michigan

4:35pm – 5:00pm  HDAC6 Inhibitor Reverses Established PN Pain in Rodent Models
Mathew Jarpe, PhD, Associate Vice President of Biology - Acetylon Pharmaceuticals, Inc.

5:05pm – 5:30pm  Pain Strategies & the BH4 Pathway
Stephen Zicha, PhD, Executive Director, Head of Translational Sciences - Quartet Medicine

5:35pm – 6:00pm  Panel Discussion & Audience Participation

6:00pm – 6:30pm  Bristol-Myers Squibb
NAV variant analysis in the FPN cohort
Samir Wadhawan, PhD, Research Investigator II - Bristol-Myers Squibb

Cocktail Reception & Dinner - Adams Room- (6th Floor)

7:00pm – 7:30pm  Cocktail Reception
7:30pm – 10:00pm  Dinner

8:30pm - Keynote Speaker:  Living with CIPN: Understanding the Patient’s Quest for Quality of Life
Ted Burns, MD, Professor of Neurology - University of Virginia
Friday September 9, 2016

7:00am – 7:45am  Breakfast – Potter’s

Session #3
Honoré Ballroom - 8:00am – 1:00pm
Cannabis & Neuropathic Pain
Moderators – David Simpson, MD – Professor of Neurology, Icahn School of Medicine Mount Sinai Medical Center &
Senda Ajroud-Driss, MD – Associate Professor, Northwestern University, Feinberg School of Medicine

TOPIC #1 – Cannabis and Neuropathic Pain: Basic Science and Clinical Trials

8:00am – 8:25am  Basic Science of Cannabis and Analgesia I  
Daniele Piomelli, PhD, Professor, Anatomy & Neurobiology  
University of California Irvine School of Medicine

8:30am – 8:55am  Basic Science of Cannabis and Analgesia II  
Andrea Hohmann, PhD, Linda & Jack Gill Chair of Neuroscience, Professor - Indiana University

9:00am – 9:25am  Cannabis in Neuropathic Pain-Focus on HIV PN  
Mark Wallace, MD, Chair, Division of Pain Medicine - University of California San Diego School of Medicine

9:30am – 9:55am  Panel Discussion & Audience Participation

9:55am – 10:15am  Break

TOPIC #2 – Medicinal Cannabis: Regulatory, Industry and Medical Perspectives

10:20am – 10:45am  Medicinal Use of Cannabis-Regulatory Perspective  
Marilyn A. Huestis, PhD, Adjunct Professor - University of Maryland

10:50am – 11:15am  Medicinal Use of Cannabis-Industry Perspective  
Nicholas Vita, CEO, & Rosemary Mazanet, MD, PhD, Chair, Scientific Advisory Board - Columbia Care, LLC

11:20am – 12:00am  Medicinal Use of Cannabis-Pro/Con  
Mark Ware, MD, MSc, Assistant Professor Family Medicine and Anesthesia - McGill University &  
Andrew Rice, MD, MB, BS, FRCA, FFPMRCA, Professor of Pain Research - Imperial College

12:05pm – 12:30pm  Panel Discussion & Audience Participation

12:30pm -1:00pm  Next Steps & Closing Remarks – Symposium Committee

1:00pm – 1:30pm  Box Lunch & Departures